Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

3756 results about "Target protein" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Target proteins are functional biomolecules that are addressed and controlled by biologically active compounds. They are used in the processes of transduction, transformation and conjugation. The identification of target proteins, the investigation of signal transduction processes and the understanding of their interaction with ligands are key elements of modern biomedical research. Since the interaction with target proteins is the molecular origin of most drugs, their particular importance for molecular biology, molecular pharmacy and pharmaceutical sciences is obvious. Target proteins control the action and the kinetic behavior of drugs within the organism. The elucidation of structure, conformational signaling and catalytic properties of particular target proteins facilitates a rational design of drugs and biotechnological processes. Known as biologicals, target proteins can also be drugs by themselves when their modification and formulation is emphasized within the pharmaceutical sciences. Finally, target protein - inducer interactions can be exploited for biomolecular transcription regulating systems in order to control for example gene therapeutic approaches.

Cationic lipids and methods for the delivery of therapeutic agents

InactiveUS8569256B2Organic active ingredientsSpecial deliveryLipid particleProtein target

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Cationic lipids and methods for the delivery of therapeutic agents

Cationic lipids and methods for the delivery of therapeutic agents

Cationic lipids and methods for the delivery of therapeutic agents

Owner:PROTIVA BIOTHERAPEUTICS

Amino lipids and methods for the delivery of nucleic acids

ActiveUS20110256175A1BiocideOrganic chemistryProtein targetLipid particle

The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Amino lipids and methods for the delivery of nucleic acids

Amino lipids and methods for the delivery of nucleic acids

Amino lipids and methods for the delivery of nucleic acids

Owner:ARBUTUS BIOPHARMA CORPORAT ION +1

Imide-based modulators of proteolysis and associated methods of use

InactiveUS20160058872A1Organic active ingredientsCompound screeningCereblonProteolytic Regulation

The description relates to imide-based compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

Imide-based modulators of proteolysis and associated methods of use

Imide-based modulators of proteolysis and associated methods of use

Imide-based modulators of proteolysis and associated methods of use

Owner:ARVINAS OPERATIONS INC

Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase

ActiveUS20140356322A1Organic active ingredientsPeptide/protein ingredientsProtein targetEnhanced degradation

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.

Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase

Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase

Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase

Owner:YALE UNIV +2

Cationic lipids and methods for the delivery of therapeutic agents

InactiveUS20120202871A1Cyclic stabilitySize requirementBiocideOrganic active ingredientsLipid formationLipid particle

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Cationic lipids and methods for the delivery of therapeutic agents

Cationic lipids and methods for the delivery of therapeutic agents

Cationic lipids and methods for the delivery of therapeutic agents

Owner:PROTIVA BIOTHERAPEUTICS

Compositions and methods for the delivery of nucleic acids

InactiveUS20110117125A1Reduce particle aggregationReduce selection requirementsAntibacterial agentsOrganic active ingredientsLipid particleProtein target

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Compositions and methods for the delivery of nucleic acids

Compositions and methods for the delivery of nucleic acids

Compositions and methods for the delivery of nucleic acids

Owner:THE UNIV OF BRITISH COLUMBIA +2

Trialkyl cationic lipids and methods of use thereof

InactiveUS8466122B2Organic active ingredientsSugar derivativesLipid formationProtein target

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Trialkyl cationic lipids and methods of use thereof

Trialkyl cationic lipids and methods of use thereof

Trialkyl cationic lipids and methods of use thereof

Owner:PROTIVA BIOTHERAPEUTICS

Functional surface coating

InactiveUS6844028B2Inhibit non-specific bindingImprove propertiesMicrobiological testing/measurementPreparing sample for investigationProtein targetBound property

Compositions and methods of preparing functional thin films or surface coatings with low non-specific binding are described. The thin films contain specified functional groups and non-specific binding repellant components. The thin films are either covalently bound to or passively adsorbed to various solid substrates. The specified functional group provides specified activity for the thin film modified solid surfaces and non-specific binding repellant components significantly reduce the non-specific binding to the thin film modified solid surfaces. Non-specific binding repellant components do not affect specified functional group's activity in the thin films. In these methods, specified functional groups are anchored to the solid substrates through a spacer. Surface coatings are also described having both non-specific protein binding properties combined with functional groups for specific binding activity thereby providing surface coating that specifically recognize target proteins but limit binding to non-specific protein.

Functional surface coating

Functional surface coating

Functional surface coating

Owner:ACCELERATED MEDICAL DIAGNOSTICS INC

Novel cationic lipids and methods of use thereof

ActiveUS20130064894A1Cyclic stabilitySize requirementPowder deliveryBiocideLipid formationLipid particle

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Novel cationic lipids and methods of use thereof

Novel cationic lipids and methods of use thereof

Novel cationic lipids and methods of use thereof

Owner:PROTIVA BIOTHERAPEUTICS

Methods for drug target screening

InactiveUS6165709AMicrobiological testing/measurementRecombinant DNA-technologyProtein targetProtein activity

The present invention provides methods for identifying targets of a drug in a cell by comparing (i) the effects of the drug on a wild-type cell, (ii) the effects on a wild-type cell of modifications to a putative target of the drug, and (iii) the effects of the drug on a wild-type cell which has had the putative target modified of the drug. In various embodiments, the effects on the cell can be determined by measuring gene expression, protein abundances, protein activities, or a combination of such measurements. In various embodiments, modifications to a putative target in the cell can be made by modifications to the genes encoding the target, modification to abundances of RNAs encoding the target, modifications to abundances of target proteins, or modifications to activities of the target proteins. The present invention also provides methods for drug development based on the methods for identifying drug targets.

Methods for drug target screening

Methods for drug target screening

Methods for drug target screening

Owner:FRED HUTCHINSON CANCER RES CENT

Compounds and methods for the enhanced degradation of targeted proteins

ActiveUS20160272639A1Senses disorderNervous disorderProtein targetEnhanced degradation

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

Compounds and methods for the enhanced degradation of targeted proteins

Compounds and methods for the enhanced degradation of targeted proteins

Compounds and methods for the enhanced degradation of targeted proteins

Owner:YALE UNIV +1

Trialkyl cationic lipids and methods of use thereof

ActiveUS20150064242A1Powder deliveryOrganic active ingredientsLipid particleProtein target

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel, trialkyl, cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses.

Trialkyl cationic lipids and methods of use thereof

Trialkyl cationic lipids and methods of use thereof

Trialkyl cationic lipids and methods of use thereof

Owner:ARBUTUS BIOPHARMA CORPORAT ION

High sensitivity quantitation of peptides by mass spectrometry

InactiveUS20040072251A1Loss of substantial specific binding capacityReduce complexitySamplingComponent separationChemical structureProtein target

The instant invention provides an economical flow-through method for determining amount of target proteins in a sample. An antibody preparation (whether polyclonal or monoclonal, or any equivalent specific binding agent) is used to capture and thus enrich a specific monitor peptide (a specific peptide fragment of a protein to be quantitated in a proteolytic digest of a complex protein sample) and an internal standard peptide (the same chemical structure but including stable isotope labels). Upon elution into a suitable mass spectrometer, the natural (sample derived) and internal standard (isotope labeled) peptides are quantitated, and their measured abundance ratio used to calculate the abundance of the monitor peptide, and its parent protein, in the initial sample

High sensitivity quantitation of peptides by mass spectrometry

High sensitivity quantitation of peptides by mass spectrometry

Owner:ANDERSON FORSCHUNG GROUP

Intein-mediated protein ligation of expressed proteins

InactiveUS6849428B1Eliminate needBacteriaFusion with post-translational modification motifProtein targetIntein

A method for the ligation of expressed proteins which utilizes inteins, for example the RIR1 intein from Methanobacterium thermotrophicum, is provided. Constructs of the Mth RIR1 intein in which either the C-terminal asparagine or N-terminal cysteine of the intein are replaced with alanine enable the facile isolation of a protein with a specified N-terminal, for example, cysteine for use in the fusion of two or more expressed proteins. The method involves the steps of generating a C-terminal thioester-tagged target protein and a second target protein having a specified N-terminal via inteins, such as the modified Mth RIR1 intein, and ligating these proteins. A similar method for producing a cyclic or polymerized protein is provided. Modified inteins engineered to cleave at their C-terminus or N-terminus, respectively, and DNA and plasmids encoding these modified inteins are also provided.

Intein-mediated protein ligation of expressed proteins

Intein-mediated protein ligation of expressed proteins

Intein-mediated protein ligation of expressed proteins

Owner:NEW ENGLAND BIOLABS

Controlling protein levels in eucaryotic organisms

InactiveUS6306663B1High activityCost-effectiveVirusesPeptide/protein ingredientsDiseaseProtein target

The invention relates to novel compounds comprising a ubiquitination recognition element and a protein binding element. The invention also relates to the use of said compounds for modulating the level and/or activity of a target protein. The compounds are useful for the treatment of disease such as infections, inflammatory conditions, cancer and genetic diseases. The compounds are also useful as insecticides and herbicides.

Controlling protein levels in eucaryotic organisms

Controlling protein levels in eucaryotic organisms

Controlling protein levels in eucaryotic organisms

Owner:WELLSTAT BIOCATALYSIS +1

Centrifugal force-based microfluidic device for protein detection and microfluidic system including the same

ActiveUS20080056949A1Bioreactor/fermenter combinationsBiological substance pretreatmentsProtein detectionProtein target

A centrifugal force-based microfluidic device for the detection of a target biomolecule and a microfluidic system including the same are provided. The device includes a body of revolution; a microfluidic structure disposed in the body of revolution including chambers, channels connecting the chambers, and valves disposed in the channels to control fluid flow, the microfluidic structures transmitting fluid using centrifugal force due to rotation of the body of revolution; and beads disposed in the microfluidic structures, the beads having capture probes on the surfaces thereof which are selectively bonded with target protein; and a detection probe disposed in the microfluidic structures and selectively bonded to the target protein, and which includes a material required to express an optical signal, wherein the microfluidic structure mixes the beads, biological samples, and the detection probe to react and washes and separates the beads after the reaction.

Centrifugal force-based microfluidic device for protein detection and microfluidic system including the same

Centrifugal force-based microfluidic device for protein detection and microfluidic system including the same

Centrifugal force-based microfluidic device for protein detection and microfluidic system including the same

Owner:PRECISIONBIOSENSOR INC

High throughput generation and screening of fully human antibody repertoire in yeast

InactiveUS6406863B1High affinityEasy to assembleMicrobiological testing/measurementImmunoglobulinsTarget peptideIn vivo

Compostions, kits and methods are provided for generating highly diverse libraries of proteins such as antibodies via homologous recombination in vivo, and screening these libraries against protein, peptide and nucleic acid targets using a two-hybrid method in yeast. The method for screening a library of tester proteins against a target protein or peptide comprises: expressing a library of tester proteins in yeast cells, each tester protein being a fusion protein comprised of a first polypeptide subunit whose sequence varies within the library, a second polypeptide subunit whose sequence varies within the library independently of the first polypeptide, and a linker peptide which links the first and second polypeptide subunits; expressing one or more target fusion proteins in the yeast cells expressing the tester proteins, each of the target fusion proteins comprising a target peptide or protein; and selecting those yeast cells in which a reporter gene is expressed, the expression of the reporter gene being activated by binding of the tester fusion protein to the target fusion protein.

High throughput generation and screening of fully human antibody repertoire in yeast

High throughput generation and screening of fully human antibody repertoire in yeast

High throughput generation and screening of fully human antibody repertoire in yeast

Owner:GENETASTIX CORP

Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof

ActiveUS20150307628A1High yieldMinimize formationHybrid immunoglobulinsAntibody mimetics/scaffoldsDiseaseProtein target

Disclosed are a CH3 domain variant pair of an antibody, a method for preparing same, and a use thereof. A mutation is induced in the CH3 domain so as to improve a yield of forming a heterodimer heavy chain constant region of an antibody. The CH3 domain heterodimer forms a heterodimer heavy chain constant region with a high efficiency of 90 to 95% or more and also has outstanding heat stability. A heterodimer heavy chain constant region including the CH3 domain heterodimer can construct a bispecific monoclonal antibody which simultaneously recognizes two kinds of antigens. The CH3 domain heterodimer and the bispecific antibody or fusion protein of an antibody constant region comprising same can be usefully applied to the treatment or prevention of a disease associated with a target antigen or a target protein.

Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof

Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof

Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof

Owner:AJOU UNIV IND ACADEMIC COOP FOUND

Novel trialkyl cationic lipids and methods of use thereof

InactiveUS20120172411A1Organic active ingredientsBiocideLipid formationLipid particle

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Novel trialkyl cationic lipids and methods of use thereof

Novel trialkyl cationic lipids and methods of use thereof

Novel trialkyl cationic lipids and methods of use thereof

Owner:PROTIVA BIOTHERAPEUTICS

Functional surface coating

InactiveUS20050100675A1Inhibit non-specific bindingRobust attachmentPretreated surfacesBiological testingProtein targetCombinatorial chemistry

Compositions and methods of preparing functional thin films or surface coatings with low non-specific binding are described. The thin films contain specified functional groups and non-specific binding repellant components. The thin films are either covalently bound to or passively adsorbed to various solid substrates. The specified functional group provides specified activity for the thin film modified solid surfaces and non-specific binding repellant components significantly reduce the non-specific binding to the thin film modified solid surfaces. Non-specific binding repellant components do not affect specified functional group's activity in the thin films. In these methods, specified functional groups are anchored to the solid substrates through a spacer. Surface coatings are also described having both non-specific protein binding properties combined with functional groups for specific binding activity thereby providing surface coating that specifically recognize target proteins but limit binding to non-specific protein.

Functional surface coating

Functional surface coating

Functional surface coating

Owner:ACCELERATED MEDICAL DIAGNOSTICS INC

Pharmaceutical composition comprising an immunoglobulin fc region as a carrier

ActiveUS20060275254A1Prolong the action timePeptide/protein ingredientsAntibody mimetics/scaffoldsProtein targetHalf-life

Disclosed is a novel use of an immunoglobulin Fe fragment, and more particularly, a pharmaceutical composition comprising an immunoglobulin Fe fragment as a carrier. The pharmaceutical composition comprising an immunoglobulin Fe fragment as a carrier remarkably extends the serum half-life of a drug while maintaining the in vivo activity of the drug at relatively high levels. Also, when the drug is a polypeptide drug, the pharmaceutical composition has less risk of inducing immune responses compared to a fusion protein of the immunoglobulin Fe fragment and a target protein, and is thus useful for developing long-acting formulations of various polypeptide drugs.

Pharmaceutical composition comprising an immunoglobulin fc region as a carrier

Pharmaceutical composition comprising an immunoglobulin fc region as a carrier

Pharmaceutical composition comprising an immunoglobulin fc region as a carrier

Owner:HANMI SCI CO LTD

Cationic lipids and methods for the delivery of therapeutic agents

InactiveUS9018187B2Organic active ingredientsOrganic chemistryLipid particleProtein target

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid in vivo. The compositions of the present invention are highly potent, thereby allowing effective know-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Cationic lipids and methods for the delivery of therapeutic agents

Cationic lipids and methods for the delivery of therapeutic agents

Cationic lipids and methods for the delivery of therapeutic agents

Owner:PROTIVA BIOTHERAPEUTICS

Trialkyl cationic lipids and methods of use thereof

ActiveUS9352042B2Powder deliveryOrganic active ingredientsLipid particleProtein target

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel, trialkyl, cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses.

Trialkyl cationic lipids and methods of use thereof

Trialkyl cationic lipids and methods of use thereof

Trialkyl cationic lipids and methods of use thereof

Owner:ARBUTUS BIOPHARMA CORPORAT ION

Cereblon ligands and bifunctional compounds comprising the same

InactiveUS20180215731A1Organic active ingredientsOrganic chemistryCereblonEnzyme binding

The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

Cereblon ligands and bifunctional compounds comprising the same

Cereblon ligands and bifunctional compounds comprising the same

Cereblon ligands and bifunctional compounds comprising the same

Owner:ARVINAS OPERATIONS INC

Cereblon ligands and bifunctional compounds comprising the same

InactiveUS20180228907A1Organic active ingredientsOrganic chemistryCereblonEnzyme binding

The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

Cereblon ligands and bifunctional compounds comprising the same

Cereblon ligands and bifunctional compounds comprising the same

Cereblon ligands and bifunctional compounds comprising the same

Owner:ARVINAS OPERATIONS INC

Proteomic analysis

InactiveUS6872574B2Reduce reactivityCompound screeningApoptosis detectionProtein targetBiological target

The present invention provides methods for analyzing proteomes, as cells or lysates. The analysis is based on the use of probes that have specificity to the active form of proteins, particularly enzymes and receptors. The probes can be identified in different ways. In accordance with the present invention, a method is provided for generating and screening compound libraries that are used for the identification of lead molecules, and for the parallel identification of their biological targets. By appending specific functionalities and/or groups to one or more binding moieties, the reactive functionalities gain binding affinity and specificity for particular proteins and classes of proteins. Such libraries of candidate compounds, referred to herein as activity-based probes, or ABPs, are used to screen for one or more desired biological activities or target proteins.

Proteomic analysis

Proteomic analysis

Proteomic analysis

Owner:THE SCRIPPS RES INST

Targeting proteins to cells expressing mannose receptors via expression in insect cells

ActiveUS7232670B2BiocidePeptide/protein ingredientsProtein targetCell selectivity

The present invention is based on the discovery that proteins produced in insect cell cultures are glycosylated in a unique manner that causes them to be selectively imported by cells that express mannose receptors on their membranes, particularly macrophages. Proteins that are selectively imported into cells containing mannose receptors are provided, as well as pharmaceutical compositions containing such proteins and methods for producing such proteins. Application of the present invention to produce proteins useful for treating lysosomal storage disorders is also disclosed. Engineering of cells to express mannose receptors so that they will selectively import proteins produced in insect cells is also taught, as well as a protein targeting system using such cells and proteins. Finally, an improved elution buffer for the purification of proteins produced in insect cells from a Concanavalin A column is provided.

Owner:ST JUDE CHILDRENS RES HOSPITAL INC

Compounds useful for promoting protein degradation and methods using same

InactiveUS20150119435A1BiocideOrganic chemistryProtein targetOxidative stress

The present invention includes compounds that act as degraders of a target protein, wherein degradation is independent of the class of the target protein or its localization. In certain embodiments, the invention comprises a compound comprising a protein degradation moiety covalently bound to a linker, wherein the ClogP of the compound is equal to or higher than 1.5. In other embodiments, the target protein contemplated within the invention comprises a posttranslational modified protein or intracellular protein. In yet other embodiments, compounds of the present invention are used to treat disease states wherein protein degradation is a viable therapeutic approach, such as cancer or any sort of oxidative stress disease state.

Compounds useful for promoting protein degradation and methods using same

Compounds useful for promoting protein degradation and methods using same

Compounds useful for promoting protein degradation and methods using same

Owner:YALE UNIV

Amino lipids and methods for the delivery of nucleic acids

InactiveUS9139554B2Antibacterial agentsOrganic active ingredientsLipid formationProtein target

The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Amino lipids and methods for the delivery of nucleic acids

Amino lipids and methods for the delivery of nucleic acids

Amino lipids and methods for the delivery of nucleic acids

Owner:ARBUTUS BIOPHARMA CORPORAT ION +1

Protein expression vector and utilization thereof

InactiveUS7029909B1Improve purification effectPolypeptide with localisation/targeting motifAnimal cellsProtein targetNucleotide

A protein expression vector containing (a) a nucleotide sequence encoding an IgG(κ) or a trypsin secretory signal peptide, (b) a nucleotide sequence encoding a polyhistidine amino acid sequence, (c) a nucleotide sequence encoding an amino acid sequence comprising amino acid residues 36–40 of SEQ ID NO:19 (Asp-Asp-Asp-Asp-Lys), which is cleavable by an enterokinase, and (d) a cloning site into which a nucleotide sequence encoding a target protein can be inserted, wherein (a), (b), (c) and (d) are assembled within the vector in the order recited.

Protein expression vector and utilization thereof

Protein expression vector and utilization thereof

Protein expression vector and utilization thereof

Owner:FUSO PHARMA INDS

Popular searches

Low dose Target protein Nucleic acid Molecular biology Therapeutic index Toxicity De ubiquitination Protein Ubiquitin ligase binding Ubiquitin ligase

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Try Eureka

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap